JPM23: Amid launch spree, Eli Lilly expects revenue growth at the 'high end of the industry,' CFO says

Eli Lilly is entering 2023 still riding a high from last year.

Amid an expansion spree thanks to launches such as Mounjaro in diabetes, the company is gearing up for “another unprecedented year,” Chief Financial Officer Anat Ashkenazi said during the J.P. Morgan Healthcare Conference.

Lilly expects to reach the market with up to four new drugs in 2023, Ashkenazi said. Those are donanemab for Alzheimer’s disease, BTK inhibitor pertibrutinib, mirikizumab for plaque psoriasis and lebrikizumab for atopic dermatitis.